Wire · opportunities
Sanofi snags FDA thumbs up for Sarclisa as 1st cancer drug delivered by on-body injector
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 10 July 2026 · Fusion42 review
Sanofi wins FDA approval for Sarclisa Escena, the first cancer drug deliverable by on-body injector, matching efficacy to its IV formulation and using Enable Injections' CirCLIQ device. The subcutaneous option positions Sarclisa to compete more directly with J&J's Darzalex Faspro in multiple myeloma treatment.
This Wire brief sits within Fusion42's coverage of Digital Health.
◆ ◆ The Wire takeaway
If you make delivery devices for large-volume injectables, Sanofi just proved the on-body injector is now table-stakes for competing oncology drugs—and J&J's five-year head start on subcutaneous Darzalex is eroding. Enable Injections owns this FDA playbook; your window to license or co-develop a competing platform is closing fast.
◆ Coverage
1 source · 10 Jul 2026
◆ Related on Wire
◆ Topics